Somatropin HGH human growth hormone up until the mid 1980's came from the pituitary glands of cadavers obtained mostly from Africa. In the mid 1980's cadaver somatropin (hgh) human growth hormone was pulled off the market after it was found to cause a rare disease called Creutzfeld-Jacob disease in the patients, mostly children, who were administering it.

In 1985 the Eli Lily pharmaceutical company managed to synthetically copy the DNA of somatropin hgh human growth hormone exactly in their lab which the human body naturally produces. Since then the only somatropin HGh human growth hormone available has been,and still is a Recombinant (biosynthetic)Somatropin hormone,generic name - Somatotropin, or Somatropin or Somatotrophin and is only available in an injectable hgh form.

1985, Keith Kelley, M.D., a research scientist demonstrated that injections of cells that secrete high amounts of somatropin hgh human growth hormone could cause the shriveled thymus glands in old rats to grow until they became as large and healthy as those of young rats. The thymus gland is the primary organ of the immune system. Immune system enhancement as a result of an increased level of somatropin hgh human growth hormone include the following: increased maturation of neutrophils; higher activity of natural killer cells; stimulation of macrophages;. increased production of red blood cells; the manufacture of new antibodies; increased production of T-cells and interleukin 2; and the greater proliferation and activity of lymphocyte cells.

Somatropin HGH human growth hormone is a protein molecule consisting of 191 amino acids. Genetic engineering, a new technology that emerged in the 1970's, enables researchers to splice human genes. The process of gene splicing enabled researchers to clone the somatropin hgH human growth hormone protein after identifying its exact sequence of DNA. After the growth hormone protein was cloned, it was then produced in drug laboratories in commercial quantities. Consequentially, biosynthetic somatropin hgh human growth hormone began to be available to medical researchers for the first time in the 1980's. This genetically engineered recombinant Somatropin HgH human growth hormone is completely identical to the Somatropin hGh human growth hormone naturally produced by the human pituitary gland and is therefore referred to as a natural somatropin hormone.

Somatropin HGH research conducted by Dr. Daniel Rudman, an endocrinologist and medical researcher from Madison, Wisconsin, conducted the original and remarkable HGH research on the effect of Somatropin HGH human growth hormone replacement therapy in humans. By the time Dr. Rudman began his work in the mid-1980's, the safety of Somatropin  growth hormone had already been well established through its use in children with human growth hormone deficiency. Dr. Rudman believed that the changes in body composition which become apparent around age 35 had to do with declining hormone levels. The only method of testing his hypothesis was to replace somatropin hgh in deficient elderly adults to ascertain if the SOMATROPIN HGH growth hormone replacement reversed some of the effects associated with aging. If somatropin hormone replacement reversed the changes in body composition (ratios of body fat and lean body mass to total body weight associated with aging, then somatropin hGh will reverse the loss of bodily structure and function that occurs with aging.More on Somatropin HGH human growth hormone saizen humatrope